Celularity regained compliance with Nasdaq’s minimum bid-price and minimum market-value requirements, closing both matters. The company’s delayed periodic reports remain an unresolved compliance issue, and Celularity says it continues work to complete those filings and restore compliance with Nasdaq’s reporting requirement.

Key Highlights

  • Nasdaq’s Listing Qualifications Staff sent written notifications on September 11 confirming the two compliance restorations.
  • K. Harold Fletcher signed the company’s report on September 14 as chief legal and strategy officer.
  • Celularity continues efforts to complete delayed periodic reports and regain compliance with Nasdaq’s reporting requirement.

Celularity Inc. (NASDAQ: CELU) has regained compliance with Nasdaq’s minimum bid-price requirement and its minimum market-value requirement for listed securities. The two listing matters are now closed, while Celularity continues work on a separate periodic-reporting deficiency.

Written notifications reached Celularity on September 11 from the Listing Qualifications Staff of Nasdaq. Celularity’s report was signed on September 14 by K. Harold Fletcher, chief legal and strategy officer. The document was executed on behalf of Celularity under the requirements of the Securities Exchange Act of 1934.

Delayed Reports Remain Outstanding

Celularity said it continues working to complete its delayed reports and restore compliance with Nasdaq’s periodic-reporting standard.